Software Service
Technology
Pharmaceutical

Simulations Plus

$20.88
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.26 (1.26%) Today
+$0.26 (1.26%) Today

Why Robinhood?

You can buy or sell SLP and other stocks, options, ETFs, and crypto commission-free!

About

Simulations Plus, Inc. engages in licensing and conducting drug research by pharmaceutical and biotechnology companies. It offers pharmaceutical, and chemical, cosmetics and food industries. Read More The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered Lancaster, CA.

Employees
95
Headquarters
Lancaster, California
Founded
1996
Market Cap
360.02M
Price-Earnings Ratio
43.93
Dividend Yield
1.15
Average Volume
62.44K
High Today
$21.07
Low Today
$20.74
Open Price
$20.74
Volume
17.26K
52 Week High
$23.95
52 Week Low
$14.25

Collections

Software Service
Technology
Pharmaceutical
Biotechnology
Cosmetics
Food
Health
Retail

News

Simply Wall St2h

Are Insiders Selling Simulations Plus, Inc. (NASDAQ:SLP) Stock?

We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we’d be remiss not to mention that insider sales have been known to precede tough periods for a business. So before you buy or sell Simulations Plus, Inc. (NASDAQ:SLP), you may well want to know whether insiders have been buying or selling. What Is Insider Buying? Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock on the marke...

0
MarketBeatMar 16

Stock Price, News, & Analysis for Simulations Plus

Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a...

0
Simply Wall StMar 11

Should Simulations Plus, Inc. (NASDAQ:SLP) Be Your Next Stock Pick?

Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Simulations Plus, Inc. (NASDAQ:SLP) due to its excellent fundamentals in more than one area. SLP is a company with great financial health as well as a an impressive history of performance. Below is a brief commentary on these key aspects. For those interested in digger a bit deeper into my commentary, read the full report on Simulations Plus here. Flawless balance sheet with solid track record...

38

Earnings

$0.05
$0.08
$0.10
$0.13
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Apr 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.